The FDA draft guidance recommends MRD and CR as endpoints for accelerated drug approval in multiple myeloma, emphasizing ...
FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.
Pulmonary embolism (PE) is a common and potentially life-threatening condition with presentations ranging from mild symptoms to circulatory collapse. Early and accurate risk stratification is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results